NCT07140016 2026-03-04A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Astellas Pharma IncPhase 1 Recruiting40 enrolled
NCT02495233 2024-11-27A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)Astellas Pharma IncPhase 1/2 Terminated10 enrolled 18 charts